The global central venous catheter market reached $3 billion in 2021 and is expected to expand at a CAGR of 6.3% from 2023 to 2030. Central venous catheters are also called central lines. It's a flexible tube inserted into the right collarbone vein and led to the superior vena cava, a key vein leading to the heart. A central venous catheter helps deliver fluids to patients. Intravenous fluids, blood transfusions, and chemotherapy are used. These devices help people who can't eat orally. Increasing cardiovascular illness and chronic kidney disease, as well as the need for prolonged intravenous therapy in critically ill patients, will boost venous catheter demand over the projection period. According to a 2021 article in Kidney International Reports, 80% of U.S. patients with the end-stage renal disease begin HD-CVC treatment. Chronic diseases increase patient flow in healthcare facilities. Due to the increasing prevalence of chronic diseases such as cardiovascular diseases and chronic renal diseases, as well as a large senior population sensitive to age-related disorders, the market for central venous catheters is expected to grow at a constant rate over the forecast period.
Manufacturers are investing in R&D to generate more effective and improved central venous catheter devices. This is likely to boost growth. Rising acceptance of innovative technology during medical operations and device implantation changes the market for central venous catheters. Ultrasound-guided insertions boost CVC safety, and efficacy, and reduce complications. Greater access to product-based solutions like quality control and infection prevention suggestions has boosted global central venous catheter market revenue. Disease load, disposable money, and understanding of surgical procedures for disease management influence these variables.
The increasing prevalence of CVDs/cardiovascular illnesses (CAD, atherosclerosis, cardiomyopathy, myocardial infarction, etc.) is a primary driver of market growth from 2020 to 2030. AHA: CVDs caused 868,662 deaths in 2017. CHD was the main cause of death in the U.S. in 2018 (42.1%), followed by stroke (17.0%), high BP (11.0%), cardiac failure (9.6%), arterial diseases (2.8%), and other CVDs (17.0%). Due to CVDs, the use of CVCs such as percutaneous central venous catheters, subclavian vein catheters, femoral venous catheters, non-tunneled percutaneous central venous catheters, triple lumen central venous catheters, subclavian central venous catheters, PICC line catheters, internal jugular vein catheters for dialysis, implanted ports, etc., as well as procedures. Increasing demand for antimicrobial catheters, technical developments, and the geriatric population is also driving the market growth. According to UNESA, there were 727Mn people 65 or older in 2020. By 2050, 1.5 billion are expected.
Browse for report at : https://www.acutemarketreports.com/report/central-venous-catheters-market
China's high incidence of CLABSI drives the central venous catheter market (CLABSI). The incidence of CLABSI in Chinese ICUs in 2021 is 1.5/1000 catheter days, according to a multicenter study. This high incidence stimulates CVC use in the country, propelling the market growth. The availability of catheters at decreased rates, favourable government support, and expanding medical operations in the country would boost the central venous catheter industry.
According to FMI, CVC catheters lead the worldwide central venous catheters market, and this trend is expected to continue. Non-tunneled CVC catheters account for 77.0% of the global market. In short-term therapy and emergency settings, non-tunneled catheters are increasingly used. Non-tunneled catheters have a large impact on the growth of the central venous catheter market due to lower treatment costs and shorter hospital stays.
Controlling and preventing intravascular catheter infections (CRI). CRIs remains a primary cause of hospital-acquired infections, leading to prolonged hospital stays, higher medical expenses, and mortality. Developing nations have much higher rates of CVC infections. Multi lumen catheters cannot feed invasive devices like pacemakers or pulmonary artery catheters. Product recalls have also hampered market growth. Cook Medical recalled 360 batches of single-lumen CVCs, pressure monitoring sets, and trays on January 6, 2016, owing to a catheter tip fracture. 17,827 gadgets were recalled globally.
Non-antimicrobial catheters held 75% of the market in 2021 and are expected to continue their lead throughout the evaluation period. This is due to consumers' rising preference for non-antimicrobial catheters due to their inexpensive pricing. Non-coated or non-antimicrobial central venous catheters are widespread. Coated or anti-microbial catheters haven't reduced CLABSI or other infections. Mass-produced non-antimicrobial catheters have minimum or no coating expenses.
In 2021, double-lumen catheters accounted for 65% of the global CVC market. Chronic double-lumen or double-catheter insertions require medium- to long-term use. With more hospital and ICU admissions, the category is suitable for long-term care patients, boosting global market share. Hospitals represented 60% of the central venous catheter market in 2021 and are predicted to grow faster throughout the forecast period. This is due to chronic diseases and age-related problems, advanced medical equipment for critical care patients, and the rapid expansion of hospitals globally.
North America, Latin America, Europe, Asia-Pacific, the Middle East, and Africa make up the central venous catheter market. The availability of central venous catheter reimbursement is expected to drive market growth during the forecast period. In 2021, the U.S. will account for 40% of the global central venous catheter market. Increasing chronic illness prevalence, high uptake of central venous catheter insertions, and the existence of major medical device manufacturers fuel the U.S. market for central venous catheters. Cancer and heart disease have risen substantially in the U.S. CDC: 6 out of 10 Americans have a chronic condition. This will raise the demand for central venous catheters. Due to an established healthcare infrastructure and insurance and reimbursement regulations for traditional medical operations, the U.S. market for central venous catheters is predicted to increase at a CAGR of 5.8% from 2023 to 2030. In 2021, Germany held a 3% share of the global central venous catheter market, which is expected to grow steadily due to frequently revised standard guidelines for central venous access, booming medical tourism, an increase in hospital stays due to chronic diseases, and technological advancements in catheters. New advancements in healthcare and practice are boosting Germany's central venous catheter sales. The fast expansion of the nation's healthcare infrastructure may also benefit central venous catheter manufacturers.
Key corporations constantly add new, creative goods to their portfolios. They're also seeking partnerships, mergers, acquisitions, and collaborations to enhance revenue and global footprint. B. Braun Melsungen AG, Becton, Dickinson and Company, ICU Medical, Inc., Poly Medicure Ltd., Teleflex Incorporated, Lepu Medical Technology Co., Ltd., Cook Group, Insung Medical, VOGT Medical, ZOLL Medical Corporation, EETA Surgical, QMD, and Kimal are key rivals. Teleflex, Becton Dickinson, and Cook Medical dominated the CVC market in 2021. Teleflex was the leading CVC competitor. Beckton Dickinson was second and Cook Medical third.
